Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report 2026

Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Overview

• Bioinformatics In In-Vitro Diagnostics (IVD) Testing market size has reached to $98.89 billion in 2025 • Expected to grow to $133.49 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Chronic Diseases Propel Growth In Bioinformatics For IVD Testing Market • Market Trend: Revolutionizing Genetic Analysis NGS Technology In Bioinformatics For IVD Testing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Bioinformatics in in vitro diagnostics (IVD) refers to the application of computational methods, data analysis, and software tools to interpret and analyze biological data generated from in vitro diagnostic tests. It involves using algorithms and statistical models to process large volumes of molecular and clinical data from diagnostic tests conducted outside the living organism (in vitro). The main types of bioinformatics in in vitro diagnostics (IVD) testing are hardware and software. Bioinformatics in IVD testing hardware refers to the physical components and devices used in laboratory and computational settings. The types of tests include blood-based tests and tissue-based tests. These are used in various applications such as cardiovascular diseases, chronic diseases, diabetes, cancer, and others.

What Is The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Growth Forecast?

The bioinformatics in in-vitro diagnostics (ivd) testing market size is expected to see strong growth in the next few years. It will grow to $133.49 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, expansion of personalized medicine diagnostics, rising investments in ai-enabled diagnostic platforms, growing use of cloud-based diagnostic analytics, increasing regulatory acceptance of digital diagnostics. Major trends in the forecast period include increasing use of AI-based diagnostic interpretation software, rising adoption of cloud-enabled ivd bioinformatics platforms, growing integration of molecular and clinical data sets, expansion of companion diagnostics analytics, enhanced focus on real-time diagnostic data processing.

Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Segmentation

1) By Component: Hardware, Software 2) By Type Of Test: Blood Based Tests, Tissue Based Tests 3) By Application: Cardiovascular Diseases, Chronic Diseases, Diabetes, Cancer, Other Applications Subsegments: 1) By Hardware: Analyzers, Laboratory Equipment, Data Storage Devices, Sensors And Detectors, Workstations And Data Processing Hardware 2) By Software: Bioinformatics Platforms, Data Management and Integration Software, Analytics And Interpretation Software, Cloud-Based Software Solutions, AI-Based Software For Diagnostics

What Is The Driver Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The increasing prevalence of cancer is expected to propel the growth of bioinformatics in the IVD testing market going forward. Cancer is a broad term to describe a group of diseases characterized by abnormal cell growth that can invade and spread to other body parts. The increasing prevalence of Cancer is due to various factors related to exposure, lifestyle, and environmental influences. Bioinformatics in IVD testing transforms cancer diagnostics by providing precise, personalized, and comprehensive genetic insights that enhance early detection, treatment decisions, and patient outcomes. For instance, in February 2024, according to World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that over 35 million new cancer cases are predicted in 2050. Therefore, the increasing prevalence of Cancer drives the bioinformatics in the IVD testing market.

Key Players In The Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market

Major companies operating in the bioinformatics in in-vitro diagnostics (ivd) testing market are Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN N.V, Agilent Technologies Inc, PerkinElmer Inc, Roche Holding AG, BGI Genomics Co Ltd, DNAnexus Inc, Seven Bridges Genomics Inc, Dassault Systèmes SE (BIOVIA), Genedata AG, Partek Inc, Data4Cure Inc, Ontoforce NV, Geneious (Biomatters), SoftGenetics LLC, Eagle Genomics Ltd, Wuxi NextCODE Genomics, Bio‑Rad Laboratories Inc, Eurofins Scientific SE

Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Trends and Insights

Major companies operating in the bioinformatics in the IVD testing market are focused on developing innovative solutions such as next-generation sequencing (NGS) technology to enhance the detection and analysis of genetic mutations, improve diagnostic accuracy, and facilitate personalized medicine approaches. Next-generation sequencing (NGS) is a high-throughput technology that allows for the rapid sequencing of entire genomes or specific regions of DNA and RNA, enabling comprehensive genetic analysis. For instance, in January 2024, QIAGEN Digital Insights, the bioinformatics division of the Netherlands-based molecular diagnostics company QIAGEN, launched LightSpeed, an ultra-fast NGS (next-generation sequencing) secondary-analysis software accelerator integrated into its CLC Genomics Workbench Premium platform. The LightSpeed module allows laboratories to process somatic cancer NGS data at unprecedented speed, converting raw sequencing files (FASTQ) into variant calls (VCF) in just minutes, while reducing cost per sample. LightSpeed supports high-throughput cancer panels and is compatible with both cloud-based and on-premises workflows, enabling bioinformatics teams to quickly analyze multiple tumor genes and biomarkers from a single sample to guide precision oncology decision-making.

What Are Latest Mergers And Acquisitions In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

In September 2024, QIAGEN N.V., a Germany-based molecular diagnostics company, collaborated with Eli Lilly and Company to create the first IVD for APOE genotyping. This collaboration aims to create the first IVD for APOE genotyping for Alzheimer’s, using QIAGEN’s QIAstat-Dx platform. It marks a new clinical application in neurodegenerative disease diagnostics and adds to QIAGEN’s partnerships in diagnostic development. Eli Lilly and Company is a US-based pharmaceutical company specializing in In-Vitro Diagnostics Testing (IVD).

Regional Outlook

North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The bioinformatics in in-vitro diagnostics (IVD) testing market consists of revenues earned by entities by providing services such as clinical decision support systems, sequence analysis, and clinical genomics software. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioinformatics in in vitro diagnostics (IVD) testing market also includes sales of sequencing tools and diagnostics tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report 2026?

The bioinformatics in in-vitro diagnostics (ivd) testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bioinformatics in in-vitro diagnostics (ivd) testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.